C07D311/74

Substituted phenethylamine derivatives

Embodiments of the present disclosure describe substituted phenethylamine derivatives, compositions comprising the substituted phenethylamine derivatives, methods of making the substituted phenethylamine derivatives, and methods of using the phenethylamine derivatives, and the like. Exemplary compounds of the present disclosure include compounds of the formula (I) and (II): ##STR00001##
wherein X, R.sup.a, R.sup.b, R.sup.c, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined elsewhere.

Substituted phenethylamine derivatives

Embodiments of the present disclosure describe substituted phenethylamine derivatives, compositions comprising the substituted phenethylamine derivatives, methods of making the substituted phenethylamine derivatives, and methods of using the phenethylamine derivatives, and the like. Exemplary compounds of the present disclosure include compounds of the formula (I) and (II): ##STR00001##
wherein X, R.sup.a, R.sup.b, R.sup.c, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined elsewhere.

COMPOUNDS AS MODULATORS OF TLR2 SIGNALING

The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disorders that are related to inflammatory signaling processes, including but not limited to misfolded proteins.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.

Polymorphs of cocrystals of epigallocatechin gallate and caffeine
10813938 · 2020-10-27 · ·

Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.

Polymorphs of cocrystals of epigallocatechin gallate and caffeine
10813938 · 2020-10-27 · ·

Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.

TETRAHYDROPYRANYL LOWER ALKYL ESTERS AND THE PRODUCTION OF SAME USING A KETENE COMPOUND
20200325112 · 2020-10-15 ·

The present invention relates to tetrahydropyranyl lower akyl esters and specifically to tetrahydropyranyl acetates, a method for preparation thereof using ketene and use thereof as fragrances and aroma substances.

TETRAHYDROPYRANYL LOWER ALKYL ESTERS AND THE PRODUCTION OF SAME USING A KETENE COMPOUND
20200325112 · 2020-10-15 ·

The present invention relates to tetrahydropyranyl lower akyl esters and specifically to tetrahydropyranyl acetates, a method for preparation thereof using ketene and use thereof as fragrances and aroma substances.

α,β-unsaturated amide compound

The present invention provides an ,-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): ##STR00001##
[wherein, A represents optionally substituted heterocyclic diyl, R.sup.1 represents hydrogen atom or optionally substituted lower alkyl, R.sup.2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents O, S, SO.sub.2, NR.sup.X1 (wherein, R.sup.X1 represents hydrogen atom or lower alkyl), CHR.sup.X2 (wherein, R.sup.X2 represents hydrogen atom or hydroxy), CHCH, CO or NHCO, and n1 and n2 are the same or different, and each represents 0 or 1].

α,β-unsaturated amide compound

The present invention provides an ,-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): ##STR00001##
[wherein, A represents optionally substituted heterocyclic diyl, R.sup.1 represents hydrogen atom or optionally substituted lower alkyl, R.sup.2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents O, S, SO.sub.2, NR.sup.X1 (wherein, R.sup.X1 represents hydrogen atom or lower alkyl), CHR.sup.X2 (wherein, R.sup.X2 represents hydrogen atom or hydroxy), CHCH, CO or NHCO, and n1 and n2 are the same or different, and each represents 0 or 1].